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The rate of glucose utilization in isolated pancreatic slets of the rat was inhibited by the ~t2-adrenoceptor 
agonists clonidine and epinephrine. Yohimbine reversed the inhibition, al or fl-adrenoceptor agonists had 
little or no effect on glucose utilization. Stimulation of muscarinic receptors by carbamylcholine reversed 
the effect of clonidine. Pertussis toxin blocked the effect of clonidine on glucose utilization, and potentiated 
the response to carbamylcholine. 8-Bromo-cAMP did not affect glucose utilization in the presence of cloni- 
dine. Thus, ~t2-adrenoceptors negatively modulate glucose utilization, and the effect is mediated by an inhibi- 
tory guanine nucleotide r gulatory protein, but not by cAMP. 
~-Adrenoceptor; Glucose utilization; N-protein; Clonidine; cyclic AMP; (Islets of Langerhans) 
1. INTRODUCTION 
The function of pancreatic islets of Langerhans 
is negatively modulated by a2-adrenoceptor 
stimulation, tr2-Adrenoceptor agonists inhibit in- 
sulin release and adenylate cyclase activity, and 
suppress intracellular Ca 2÷ levels [1-3]. However, 
the addition of exogenous cAMP analogues or the 
stimulation of adenylate cyclase with forskolin 
does not reverse the effect of ~2-adrenergic 
stimulation on insulin release, even though in- 
tracellular Ca 2+ levels are elevated [3-5]. Thus, 
ce2-adrenoceptors mediate cellular mechanisms in 
addition to, and distal to, adenylate cyclase. 
Glucose is the primary physiological stimulus 
for insulin release, which is directly correlated with 
glucose utilization [6,7]. The present study was 
undertaken to determine whether the modulation 
of insulin release by the autonomic nervous ystem 
in pancreatic islets is mediated by changes in 
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glucose utilization. The results of this study 
demonstrate that a~z-adrenoceptors exert specific 
effects on the rate of glucose utilization which are 
modulated by an inhibitory guanine nucleotide 
regulatory protein. 
2. MATERIALS AND METHODS 
2.1. Materials 
Pertussis toxin was obtained from List 
Biological Laboratories (Campbell, CA); D- 
[5-3H]glucose was obtained from American 
Radiolabeled Chemicals (St. Louis, MO); col- 
lagenase from Clostridium histolyticum was from 
Serva (Heidelberg); clonidine, yohimbine, isobu- 
tylmethylxanthine, and carbamylcholine were 
obtained from Sigma (St. Louis, MO); prazosin 
hydrochloride was a gift from N. Belcher, Pfizer 
Inc. (Groton, CT); DL-phenylephrine HC1 was 
from Winthrop Laboratories (New York, NY). 
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2.2. Methods 
Pancreatic islets were isolated from excised pan- 
creata of male Sprague-Dawley rats by collagenase 
digestion as in [8]. Equal batches of isolated islets 
were incubated in Krebs-Ringer bicarbonate (KRB) 
buffer containing 16 mM Hepes, 1 or 10 mM D- 
[5-3H]glucose~ and 0.01070 bovine serum albumin, 
and adjusted to pH 7.4 after equilibration with 
O2-CO2 (19: 1) at 37°C. [5-3H]Glucose is 
metabolized through glycolysis and 3H20 is pro- 
duced. Quantitation of the 3H20 produced is con- 
verted into fmol glucose utilized, based upon the 
specific activity of the glucose in the incubation 
medium [7,9,10]. In this study, the rate of glucose 
utilization was determined between 25 and 45 min 
when glucose utilization is linear [9]. Adrenergic 
agents, including agonists and antagonists, were 
added 20 min prior to [3H]glucose and were pre- 
sent throughout the incubation. Islets were prein- 
cubated with pertussis toxin for 90 min prior to 
[3H]glucose, since there is a lag period of 60 min 
before the action of the toxin is expressed [11]; the 
toxin was also present throughout the remainder of 
the experiment. Carbamylcholine and 8-Br-cAMP 
were added to the islets after 25 min of incubation 
with [3H]glucose. Islet DNA content was determin- 
ed as described [9]. Statistical analysis of the data 
was carried out using a two-tailed Student's t-test 
(paired or unpaired). 
3. RESULTS 
Isolated pancreatic islets incubated with 10 mM 
[3H]glucose had a higher rate of glucose utilization 
compared to islets with 1 mM [3H]glucose (fig. 1). 
The addition of the te2-adrenoceptor agonist 
clonidine to islets incubated with 10 mM [3H]glu- 
cose inhibited glucose utilization by 4007o (fig.l). 
Yohimbine, an a~2-adrenoceptor antagonist, com- 
pletely reversed the effects of clonidine on glucose 
utilization (fig.l). The fl-adrenoceptor agonist, 
isoproterenol, did not affect glucose utilization 
(fig. 1). Moreover, ce2-adrenoceptor stimulation by 
the physiological agonist epinephrine, in the 
presence of the cel-adrenoceptor antagonist prazo- 
sin and the fl-adrenoceptor antagonist proprano- 
1ol, also inhibited glucose utilization (table 1A). 
The response to epinephrine was inhibited by 
yohimbine (table 1A). Glucose utilization in the 
presence of propranolol and prazosin (table 1A) 
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Fig.l. Effects of adrenergic agents on islet glucose 
utilization. Islets were incubated in buffer containing 
[3H]glucose (Glu) at the concentration i dicated, in the 
absence or presence of clonidine (Clon) (l/zM), 
yohimbine (Yoh) (10/zM), phenylephrine (PE) (1/zM), 
or isoproterenol (Iso) (10/zM). Values are means _+ SE 
for the number of different experimental determinations 
shown at the base of each bar. 
Table 1 
Effect of adrenoceptor stimulation and 8-Br-cAMP on 
islet glucose utilization 
Treatment Rate of glucose (n) 
utilization 
(fmol glucose/min 
per ng DNA) 
A 
B 
Prop, Praz 44 _+ 3 (16) 
Epi, Prop, Praz 34 _+ 3 b (16) 
Epi, Prop, Praz, Yoh 42 _+ 5 (5) 
Praz 55 + 11 (6) 
Clon, Praz 31 _+ 3 a (13) 
Clon, Praz, 8-Br-cAMP 34 + 3 a (10) 
Islets were incubated in Krebs buffer containing 10 mM 
[3H]glucose and the presence or absence of propranolol 
(Prop) (1/zM), prazosin (Praz) (1/zM), epinephrine 
(Epi) (1/~M), yohimbine (Yoh) (10/zM), clonidine 
(Clon) (1/zM), or 8-Br-cAMP (0.2 mM), as indicated. 
Values are the means + SE for the number of different 
experimental determinations (n). P values (a <0.02, 
b <0.01) indicate the differences from Prop plus Praz- 
treated islets in (A), or from Praz-treated islets in (B), 
and were determined by Student's t-test 
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Fig.2. Effects of carbamylcholine and pertussis toxin on 
islet glucose utilization. Islets were incubated with 
10 mM [3H]glucose in the absence (control) or presence 
of pertussis toxin (PT) (1.5-3/zg/ml), clonidine (Clon) 
(l/zM), or carbamylcholine (CCh) (10/zM) plus iso- 
butylmethylxanthine (0.1 mM), as indicated. Values are 
means + SE for the number of different experimental 
determinations shown at the base of each bar. 
was comparable to control values obtained in islets 
exposed to 10 mM glucose. Moreover, prazosin 
did not affect the response to clonidine (table 1B). 
In addition, 8-Br-cAMP did not alter the effect of 
clonidine on glucose utilization (table 1B). More- 
over, the rate of glucose utilization in the presence 
of the cel-adrenoceptor stimulus phenylephrine 
plus yohimbine was comparable to that observed 
in control islets (fig.l). 
To determine whether the effects of clonidine on 
glucose utilization are mediated by the inhibitory 
guanine nucleotide binding regulatory protein (Ni), 
islets were incubated with pertussis toxin, an in- 
hibitor of Ni. Pertussis toxin did not change 
glucose utilization compared to control values 
(fig.2). However, pertussis toxin completely 
blocked the inhibitory effects of clonidine on 
glucose utilization (fig.2). The muscarinic receptor 
agonist, carbamylcholine, reversed the inhibitory 
effect of clonidine on glucose utilization, and per- 
tussis toxin enhanced this effect of carbamyl- 
choline (fig.2). Since preliminary studies indicate 
that isobutylmethylxanthine augments the re- 
sponse to carbamylcholine (not shown), this 
phosphodiesterase inhibitor was included in the 
carbamylcholine xperiments. Carbamylcholine 
(10/zM) did not significantly affect basal (10 mM) 
glucose utilization (not shown). 
4. DISCUSSION 
These results demonstrate that stimulation of 
tr2-adrenoceptors in the pancreatic islet suppresses 
glucose utilization. Although adenylate cyclase can 
be inhibited by ~z-adrenergic agonists, this 
response plays a minor role in insulin release since 
diminished cAMP levels alone do not correlate 
with the suppression of insulin secretion [3-5]. 
Since insulin release is directly modulated by 
glucose phosphorylation a d metabolism, the pre- 
sent data suggest that ce2-adrenergic receptor 
stimulation reduces insulin release through the in- 
hibition of glucose utilization. The response to 
ce2-adrenoceptor agonists is specific since neither 
Oel- nor ~-adrenoceptor agonists affected glucose 
utilization, and the effect was inhibited by an c~2-, 
but not by an eel-, adrenergic antagonist. 
Moreover, the inhibition of adenylate cyclase by 
clonidine probably did not mediate the effects of 
this agent on glucose utilization since 8-Br-cAMP 
did not alter the response to clonidine. 
The experiments utilizing pertussis toxin 
demonstrate that ce2-adrenoceptor effects on 
glucose utilization are mediated by an inhibitory 
guanine nucleotide regulatory protein, No or Ni. 
Pertussis toxin ribosylates and inactivates certain 
N-proteins, and this toxin also reversed the effects 
of clonidine on glucose utilization, and restores in- 
sulin release [ll]. However, the activation of 
adenylate cyclase or the addition of exogenous 
cAMP analogues does not antagonize the cellular 
inhibition by te2-adrenergic agonists [4,5]. 
Therefore, it is likely that islet a,2-adrenoceptor- 
associated inhibitory N-protein has pluralistic 
functions, perhaps affecting glucose transport, or 
phosphodiesterase activity [12]. However, per- 
tussis toxin did not change basal glucose utiliza- 
tion, suggesting a specific interaction with 
ot2-adrenoceptor-mediated cellular events. 
Carbamylcholine reverses the inhibitory effect 
of clonidine on glucose utilization (fig.2) and 
potentiates the insulin secretory response after ot- 
adrenoceptor antagonism [ 13]. Cholinergic 
stimulation of cells can also induce changes in 
polyphosphoinositide turnover, Ca 2+ mobiliza- 
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tion, and cGMP levels [14,15]. It is not known 
which of these effects, or others, mediate the 
changes observed in glucose utilization with 
cholinergic stimulation. However, the enhanced 
cholinergic response in the presence of pertussis 
toxin suggests that carbamylcholine not only an- 
tagonizes the clonidine inhibition but also 
stimulates the production of a positive modulator 
of glucose utilization which fully expresses its ef- 
fect in the presence of pertussis toxin. 
In conclusion, this study is the first to 
demonstrate that in pancreatic islets ce2-adreno- 
ceptors express an inhibitory action on the rate of 
glucose utilization. The effect is antagonized by 
cholinergic receptor stimulation, and mediated by 
an inhibitory guanine nucleotide regulatory pro- 
tein through a mechanism that does not involve 
cAMP. 
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